ClinicalTrials.gg
RecruitingNCT07204457Updated Dec 1, 2025

Immunogenicity and Safety of Meningococcal Conjugate Vaccine (EG-MCV4) in Healthy Adults Aged 19 to 55 Years Old

A Phase 2/3 interventional study of EG-MCV4 and Menveo in Meningococcal Infections, sponsored by EyeGene Inc.. Recruiting at 1 site in South Korea. Open to participants aged 19 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-12-01.

Sponsored by EyeGene Inc. · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
1,123
Allocation
Randomized
Ages
19 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Meningococcal Infections with a site in Korea, Republic of — 1 open to participants now, 2 under way, 1 of them phase 3. Meningococcal Infections · Korea, Republic of.

Planned enrollment
4th of 12
1,123 · median 375
Started
2025
the only one that year
Phase 2/3
Only one
of the 12
Registered
12th of 12
by date
Lead sponsor
1 of 12
EyeGene Inc.

Among the 12 studies in Meningococcal Infections with a site in Korea, Republic of, this one is the 4th largest by planned enrollment, is the only one that started in 2025, is the only one in phase 2/3, and was the 12th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

1 of the 12 studies in Meningococcal Infections with a site in Korea, Republic of is open now.

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 19 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Meningococcal Infections with a site in Korea, Republic of, or all of them as a file.
02

Study summary

Phase 2/3 study to evaluate immunogenicity and safety in healthy adult participants following a single dose administration of Meningococcal (groups A, C, W-135, and Y) conjugate vaccine

03

Conditions studied

  • Meningococcal Infections

Keywords

  • Meningococcal Vaccines
  • Vaccines, Conjugate
  • Bacterial Vaccines
  • Vaccines
  • Bacterial Infections
  • Meningococcal Disease
  • Neiseriaceae Infections
  • Gram-Negative Bacterial Infections
  • Infections
  • Biological Products
04

Who can participate

Ages eligible
19 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and females aged 19 to 55 years.
  • Individuals who have been fully informed about the clinical trial, understand the details, and voluntarily agree to participate by providing written .
  • Individuals who are available for all scheduled visits, including phone calls and in-person appointments, for the duration of the study.

Exclusion criteria

Exclusion Criteria:

  • History of prior disease caused by N. meningitidis.
  • Contact with a person infected with N. meningitidis within 60 days of screening.
  • Prior receipt of a meningococcal vaccine or a vaccine containing a meningococcal antigen.
  • History of or planned vaccination with any other vaccine within 4 weeks before or after administration of the product.
  • History of fever (≥ 38°C) within 3 days of screening, or a history of a significant acute infectious disease within 7 days of screening, or a chronic infectious disease within 4 weeks of screening.
  • History of or C at the time of screening.
  • Presence of any significant acute, chronic, or progressive disease that, in the opinion of the investigator, could interfere with the conduct or completion of the study.
  • History of or high-risk malignant disease within 5 years before the investigational product administration.
  • History of epilepsy, progressive neurological disease, or Guillain-Barré Syndrome.
  • History of anaphylaxis.
  • History of systemic urticaria within 5 years of the investigational product administration.
  • to the active substance, diphtheria toxoid (CRM197), or any other , or a history of a life-threatening reaction to a vaccine containing similar components.
  • Hypersensitivity to the investigational vaccine, any of its components, or latex.
  • History of any therapy that could affect the immune system within 6 months of screening.
  • History of immunodeficiency disease, or a family history of such a disease.
  • Receipt of any parenteral immunoglobulin preparation, blood product, or plasma derivatives within 90 days of screening, or planned administration during the study period.
  • History of -related or hemorrhagic disorders or a history of excessive bleeding or bruising after intramuscular injection or venipuncture.
  • Current treatment with anticoagulants or new antiplatelet agents.
  • History of organ or bone marrow transplantation.
  • Suspected history of drug or alcohol abuse within 1 year before the investigational product administration.
  • Individuals unwilling to use a medically acceptable method of for the duration of the clinical trial.
  • Pregnant or lactating women.
  • Receipt or planned receipt/application of another investigational drug or medical device within 6 months prior to study participation.
  • Presence of a significant abnormality on a screening test, or any other reason that, in the opinion of the investigator, makes the individual unsuitable for the study.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
1,123 participants (estimated)

Study arms

  • Experimental
    EG-MCV4 (Test group 1)

    Healthy adults received 0.5 mL single intramuscular dose on Day 0.

    Biological: EG-MCV4

  • Experimental
    EG-MCV4 (Test group 2)

    Healthy adults received 0.25 mL single intramuscular dose on Day 0.

    Biological: EG-MCV4

  • Active comparator
    Menveo

    Healthy adults received 0.5 mL single intramuscular dose on Day 0.

    Biological: Menveo

Interventions

  • BiologicalEG-MCV4

    single intramuscular dose on Day 0

    Also known as: Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine

  • BiologicalMenveo

    single intramuscular dose on Day 0

    Also known as: Meningococcal(Groups A, C, W-135, and Y) Conjugate Vaccine

06

What researchers measure

Primary outcomes

  1. Seroresponse

    * Part 1: * The proportion of subjects achieving a seroresponse as measured by hSBA and rSBA * Part 2: * The proportion of subjects achieving a seroresponse as measured by rSBA

    Time frame: 28 days after the vaccination

07

Study locations

1 of 1 sites recruiting
  • The Catholic University of Eunpyeong St.Mary's Hospital
    Seoul, South Korea
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Oct 2025 (actual). Primary completion is estimated for Sep 2026, 11 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 25, 2025
First posted
Oct 2, 2025
StartActual
Oct 15, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Jun 2027
Last update
Dec 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07204457
Lead sponsor
EyeGene Inc.
Collaborators
BMI Korea
Responsible party
Sponsor
First posted
Oct 2, 2025
Start date
Oct 15, 2025
Primary completion
Sep 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Dec 1, 2025

Study contacts

Jooyoung Park
Contact
jypark@eyegene.co.kr
+82-2-322-1687
Kyung-Hee Lee
Contact
seagreen@eyegene.co.kr
+82-2-322-1687

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion